Discovery of Highly Potent Liver X Receptor beta Agonists.
Kick, E.K., Busch, B.B., Martin, R., Stevens, W.C., Bollu, V., Xie, Y., Boren, B.C., Nyman, M.C., Nanao, M.H., Nguyen, L., Plonowski, A., Schulman, I.G., Yan, G., Zhang, H., Hou, X., Valente, M.N., Narayanan, R., Behnia, K., Rodrigues, A.D., Brock, B., Smalley, J., Cantor, G.H., Lupisella, J., Sleph, P., Grimm, D., Ostrowski, J., Wexler, R.R., Kirchgessner, T., Mohan, R.(2016) ACS Med Chem Lett 7: 1207-1212
- PubMed: 27994765 
- DOI: 10.1021/acsmedchemlett.6b00234
- Primary Citation of Related Structures:  
5JY3 - PubMed Abstract: 
Introducing a uniquely substituted phenyl sulfone into a series of biphenyl imidazole liver X receptor (LXR) agonists afforded a dramatic potency improvement for induction of ATP binding cassette transporters, ABCA1 and ABCG1, in human whole blood. The agonist series demonstrated robust LXRβ activity (>70%) with low partial LXRα agonist activity (<25%) in cell assays, providing a window between desired blood cell ABCG1 gene induction in cynomolgus monkeys and modest elevation of plasma triglycerides for agonist 15 ...